BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.
Vaccination may not protect all recipients.
EXPLORE CLINICAL DATA
BEXSERO demonstrated serum bactericidal activity against 3 strains selected to measure responses to 3 respective vaccine antigens prevalent among strains in the US.1,*
*Immune response data were recorded for antigens fHbp, NadA, and PorA P1.4. However, a suitable strain for assessing immune response was not available for NHBA-specific antibodies.1